Q32 Bio (QTTB) Operating Income Growth (3y) (2020 - 2026)
Q32 Bio (QTTB) Operating Income Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - | 16.96% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.85 Bn | 467.06 Bn | 1.35 Bn | 38.78% |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.04 Bn | 2.59 Bn | 13.47% |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.28 Bn | 3.31 Bn | -12.10% |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | 69.02% |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.47 Bn | 959.66 Mn | 55.96% |
| 10 | Q32 Bio | 215.52 Mn | 164.77 Mn | - | -1.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.55% |
| Dec 31, 2025 | 49.33% |
| Sep 30, 2025 | 38.68% |
| Jun 30, 2025 | 31.32% |
| Mar 31, 2025 | 31.24% |
| Dec 31, 2024 | 24.40% |
| Sep 30, 2024 | 15.02% |
| Jun 30, 2024 | 16.29% |
| Mar 31, 2024 | -137.28% |
| Dec 31, 2023 | 4.68% |
| Sep 30, 2023 | 34.91% |
| Jun 30, 2023 | 41.15% |
| Mar 31, 2023 | 41.32% |
| Dec 31, 2022 | -10.51% |
| Sep 30, 2022 | -1.65% |
| Jun 30, 2022 | -0.40% |
| Mar 31, 2022 | -14.40% |
| Dec 31, 2021 | -18.57% |
| Sep 30, 2021 | -25.17% |
| Jun 30, 2021 | -31.54% |